AtriCure, Inc. (ATRC) CSO sells 6,000 shares at $38.88 of stock

Rhea-AI Filing Summary

AtriCure Chief Scientific Officer Vinayak Doraiswamy sold 6,000 shares of common stock on July 28, 2026 in a sale classified as an open-market or private transaction at a weighted average price of $38.88 per share, with individual trades between $38.87 and $38.92. After this transaction, he directly holds 86,511 shares of AtriCure common stock.

Insider Trade Summary

Net Seller: 6,000 shares

Net Sell 1 txn

Insider Doraiswamy Vinayak

Role Chief Scientific Officer

Sold 6,000 shs ($233K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	6,000	$38.88	$233K

Holdings After Transaction: Common Stock — 86,511 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 6000 shares Weighted average sale price: $38.88 per share Post-transaction holdings: 86511 shares +1 more

4 metrics

Shares sold 6000 shares Common stock sold by CSO on July 28, 2026

Weighted average sale price $38.88 per share Average price for the 6,000-share sale

Post-transaction holdings 86511 shares Common shares directly held after the sale

Trade price range $38.87–$38.92 per share Range of prices for multiple trades in the sale

Key Terms

weighted average sales price, open market or private transaction, multiple trades

3 terms

weighted average sales price financial

"The price reported above reflects the weighted average sales price."

open market or private transaction financial

"Transaction code description: Sale in open market or private transaction"

multiple trades financial

"This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:58 PM Accepted by SEC EDGAR 07/30/2026 - 04:57 PM Learn about SEC filing dates

FAQ

What insider stock transaction did AtriCure (ATRC) report for July 28, 2026?

AtriCure reported that Chief Scientific Officer Vinayak Doraiswamy sold 6,000 shares of common stock on July 28, 2026. The sale was reported as an open-market or private transaction at a weighted average price of $38.88 per share.

How many AtriCure (ATRC) shares did the CSO sell and at what price?

Vinayak Doraiswamy sold 6,000 AtriCure shares at a weighted average price of $38.88 per share. The Form 4 notes that individual trade prices ranged from $38.87 to $38.92 per share.

What is Vinayak Doraiswamy’s remaining AtriCure (ATRC) shareholding after the sale?

Following the reported sale, Vinayak Doraiswamy directly holds 86,511 shares of AtriCure common stock. This post-transaction balance is disclosed in the Form 4 as his direct ownership position.

Were the AtriCure (ATRC) insider sales executed in multiple trades?

Yes. The Form 4 footnote states the 6,000-share sale was executed in multiple trades at prices from $38.87 to $38.92. The reported $38.88 figure represents the weighted average sales price.

Does this AtriCure (ATRC) Form 4 include any derivative security transactions?

No. The Form 4 reports only a single sale of common stock totaling 6,000 shares. The derivative security section is empty, indicating no options, warrants, or other derivative transactions were reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		S		6,000	D	$38.88(1)	86,511	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Vinayak S. Doraiswamy	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)